Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
Provided By GlobeNewswire
Last update: Mar 14, 2025
-- No Shareholder Action Required at This Time --
PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders.
Read more at globenewswire.com25.45
-0.45 (-1.74%)
Find more stocks in the Stock Screener
PCRX Latest News and Analysis
8 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued.Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
15 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
17 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.
